Volume | 582,160 |
|
|||||
News | - | ||||||
Day High | 18.34 | Low High |
|||||
Day Low | 17.92 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Myriad Genetics Inc | MYGN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
18.34 | 17.92 | 18.34 | 17.98 | 18.63 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
8,393 | 582,160 | $ 18.09 | $ 10,528,385 | - | 13.82 - 24.21 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:11:00 | formt | 3,509 | $ 17.98 | USD |
Myriad Genetics (MYGN) Options Flow Summary
Myriad Genetics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.62B | 89.87M | - | 753.2M | -263.3M | -2.93 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Myriad Genetics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MYGN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 18.57 | 19.00 | 17.92 | 18.54 | 521,213 | -0.59 | -3.18% |
1 Month | 21.35 | 21.67 | 17.92 | 19.73 | 544,344 | -3.37 | -15.78% |
3 Months | 21.56 | 23.75 | 17.92 | 21.42 | 623,869 | -3.58 | -16.60% |
6 Months | 15.52 | 23.75 | 13.82 | 19.89 | 667,820 | 2.46 | 15.85% |
1 Year | 21.642 | 24.21 | 13.82 | 19.68 | 597,924 | -3.66 | -16.92% |
3 Years | 30.37 | 36.9547 | 13.82 | 22.67 | 577,639 | -12.39 | -40.80% |
5 Years | 31.99 | 48.40 | 9.24 | 22.44 | 733,336 | -14.01 | -43.79% |
Myriad Genetics Description
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Prequel, with is a noninvasive prenatal test; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies. |